Dexmedetomidine Attenuates LPS-Induced Monocyte-Endothelial Adherence via Inhibiting Cx43/PKC-α/NOX2/ROS Signaling Pathway in Monocytes

Figure 4

Dexmedetomidine attenuates Cx43 expression in U937 monocytes. With the downregulation of Cx43 expression, the PKC-α/NOX2/ROS signaling pathway is also inhibited, ultimately leading to VAL-4 and LFA-1 expression decrease and U937-HUVEC adhesion reduction. Inhibiting Cx43 expression in U937 monocytes with siRNA-Cx43, (a) Cx43, PKC-α, and NOX2 expressions are decreased (NC: negative control, , vs. control; ^# vs. the LPS group); (b) the level of ROS is decreased (NC: negative control, , vs. control; ^# vs. the LPS group); (c) VLA-4 and LFA-1 expressions are decreased (NC: negative control, , vs. control; ^# vs. the LPS group); (d) U937-HUVEC adhesion is decreased (NC: negative control, , vs. control; ^# vs. the LPS group). (e) Effects of dexmedetomidine on Cx43 expression in U937 monocytes (, vs. control; ^# vs. the LPS group; ^& vs. the 0.1 nM dexmedetomidine group).

(a)

(b)

(c)

(d)

(e)